natgillin/translations-raw huggingface dataset:
Inhibition of CYP 2C9 with firstdose tipranavir /r, then induction of CYP 2C9 with steady-state tipranavir/r
Inhibicija CYP 2C9 prvom dozom tipranavira/r, zatim indukcija CYP 2C9 tipranavirom/r u stanju ravnoteže
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase dihydroergotamine, ergonovine, ergotamine and methylergonovine concentrations.
Temeljem teoretskih razmatranja, očekuje se da tipranavir s niskom dozom ritonavira povećava koncentracije dihidroergotamina, ergonovina, ergotamina i metilergonovina.
Since levels of ethinyl oestradiol are decreased, the co-administration of Aptivus co-administered with low dose ritonavir is not recommended.
S obzirom da su vrijednosti etinilestradiola snižene, istodobna primjena Aptivusa s niskom dozom ritonavira se ne preporuča.
Your child should continue to take Aptivus for as long as your child's doctor tells him/her.
Vaše dijete treba nastaviti uzimati Aptivus toliko dugo koliko je propisao djetetov liječnik.
In both studies, a total of 67% patient viruses were resistant and 22% were possibly resistant to the pre-selected comparator PIs.
Medijan prethodno rabljenih NRTI-a iznosio je 6, NNRTI-a 1 i IP-a 4. U oba ispitivanja, ukupno 67% bolesnika imalo je rezistentne viruse, a 22% moguće rezistentne na prethodno odabrane kontrolne IP.
propylene glycol, mono/diglycerides of caprylic/capric acid, sucralose, ascorbic acid, Butter
mono/digliceridi kaprilatne/kaprinske kiseline, sukraloza, askorbatna kiselina, okusi maslaca metvice i maslaca karamele.
- If you have any further questions, please ask your child's doctor or pharmacist.
Ako imate dodatnih pitanja, obratite se djetetovom liječniku ili ljekarniku.
Transient inhibition of P-gp by tipranavir/r, followed by induction of P-gp by tipranavir/r at steadystate
Prolazna inhibicija P-gp putem tipranavira/r, iza čega slijedi indukcija P-gp putem tipranavira/r u stanju ravnoteže
150 mg/m 2 ritonavir, twice daily.
500 mg uz ritonavir 200 mg.
In one particular in vitro resistance experiment, an HIV-1 isolate that was 87-fold resistant to tipranavir was selected after 9 months, and contained 10 mutations in the protease: L10F, I13V, V32I, L33F, M36I, K45I, I54V/T, A71V, V82L, I84V as well as a mutation in the gag polyprotein CA/P2 cleavage site.
U jednom in vitro ispitivanju, HIV-1 izolat, koji je bio 87 puta otporniji na tipranavir (od uobičajeno osjetljivih sojeva) odabran je nakon 9 mjeseci, te je sadržavao 10 mutacija u proteazi: L10F, I13V, V32I, L33F, M36I, K45I, I54V/T, A71V, V82L, I84V kao i mutaciju na gag poliproteinskom CA/P2 mjestu na kojem tipranavir cijepa proteazu.
Concomitant administration of Aptivus, co-administered with low dose ritonavir, and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Istodobna primjena Aptivusa s niskom dozom ritonavira i ovih glukokortikoida se ne preporučuju, osim ako potencijalni pozitivni učinci liječenja ne nadilaze rizik od sistemskih kortikosteroidnih učinaka (vidjeti dio 4.4).
Through a series of multiple stepwise regression analyses of baseline and on-treatment genotypes from all clinical studies, 16 amino acids have been associated with reduced tipranavir susceptibility and/or reduced 48-week viral load response: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D and 84V.
Stupnjevita multivarijatna regresijska analiza združenosti genotipova (određenih na početku liječenja ili tijekom liječenja) i terapijskog odgovora ukazala je da je 16 aminokiselina združeno sa smanjenom osjetljivošću na tipranavir i/ili sa manjim odgovorom u smislu broja virusnih replika nakon 48 tjedana liječenja: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D i 84V.
Liver monitoring
Praćenje funkcije jetre
Digoxin 0.25 mg QD iv
Digoksin 0,25 mg QD i.v.
NAME OF THE MEDICINAL PRODUCT Aptivus 100 mg/ml oral solution
NAZIV LIJEKA Aptivus 100 mg/ml oralna otopina
Therefore, the concomitant use of zidovudine or abacavir with Aptivus, co-administered with low dose ritonavir, is not-recommended unless there are no other available NRTIs suitable for patient management (see section 4.5).
Stoga se istodobna primjena zidovudina ili abakavira s Aptivusom, uz nisku dozu ritonavira, ne preporuča, osim ako su oni jedini NRTI prikladni za zbrinjavanje bolesnika (vidjeti dio 4.5).
The most frequently reported moderate or severe adverse reactions in the 48 week analyses are noted below.
Najčešće umjerene do teške nuspojave zabilježene tijekom 48 tjedana navedene su u tablici.
Co-administration of etravirine and Aptivus/ritonavir is not recommended.
Istodobna primjena etravirina i Aptivusa/ritonavira se ne preporučuje.
Due to the marked hepatotoxicity of bosentan and the potential for increasing the liver toxicity associated with Aptivus,co-administered with low dose ritonavir, this combination is not recommended.
Zbog izražene hepatotoksičnosti bosentana i moguće povećane hepatotoksičnosti Aptivusa s niskom dozom ritonavira, ova kombinacija se ne preporučuje.
These medicines are used to treat anxiety or sleep disorders - ergot derivatives (used to treat headaches) - astemizole or terfenadine (used to treat allergies or hay fever) - simvastatin or lovastatin (used to lower blood cholesterol) - amiodarone, bepridil, flecainide, propafenone or quinidine (used to treat heart disorders) - metoprolol (used to treat heart failure) - alfuzosin and sildenafil (when used to treat a rare blood vessel disorder characterized by increased pressure in the pulmonary artery) - colchicine (when used to treat gout flares in patients with kidney or liver disease).
Ovi lijekovi se primjenjuju u liječenju anksioznosti ili poremećaja spavanja - derivate ergota (primjenjuju se u liječenju glavobolja) - astemizol ili terfenadin (primjenjuju se u liječenju alergija ili peludne groznice) - simvastatin ili lovastatin (primjenjuju se za snižavanje kolesterola u krvi) - amiodaron, bepridil, flekainid, propafenon, ili kinidin (primjenjuju se u liječenju srčanih poremećaja) - metoprolol (primjenjuje se u liječenju zatajenja srca) - alfuzosin i sildenafil (kada se primjenjuju u liječenju rijetkog poremećaja krvnih žila koji se karakterizira povišenim tlakom u plućnoj arteriji) - kolhicin (kada se primjenjuje u liječenju naglih pogoršanja gihta u bolesnika s bolešću bubrega ili jetre).
Dosing of Aptivus, co-administered with low dose ritonavir, with antacids should be separated by at least a two hours time interval.
Doziranje Aptivusa s niskom dozom ritonavira i antacida potrebno je odvojiti u minimalnom intervalu od dva sata.
Saquinavir Cmax ↓ 70% Saquinavir AUC ↓ 76% Saquinavir Cmin ↓ 82%
Sakvinavir Cmax ↓ 70% Sakvinavir AUC ↓ 76% Sakvinavir Cmin ↓ 82%
Alternative or additional contraceptive measures are to be used when oestrogen based oral contraceptives are co-administered with Aptivus co-administered with low dose ritonavir (see section 4.5).
Potrebno je primjenjivati alternativne ili dodatne kontraceptivne mjere kad se oralni kontraceptivi na bazi estrogena primjenjuju istodobno s Aptivusom i ritonavirom (vidjeti dio 4.5).
You should therefore carefully read the Package Leaflets of ritonavir and your other antiretroviral medicines.
Prema tome, pažljivo pročitajte upute koje se prilažu uz ritonavir i druge antiretrovirusne lijekove koje primjenjujete.
Dosage increase and long-term use of meperidine with Aptivus, coadministered with low dose ritonavir, are not recommended due to the increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g. seizures).
U bolesnika liječenih Aptivusom, uz nisku dozu ritonavira ne preporučuje se istodobna dugotrajna primjena meperidina ili povišenje doza meperidina zbog povećanih koncentracija metabolita normeperidina koji ima analgetski učinak i stimulira središnji živčani sustav (npr. epileptični napadaji).
Overall population FAS
Ukupna populacija Svi ispitanici PP
Muscle disorders
Poremećaji mišića
Do not take products containing St John's wort (a herbal remedy for depression).
Ne uzimajte proizvode koji sadrže gospinu travu (biljni lijek protiv depresije), jer ona može spriječiti ispravno djelovanje Aptivusa.
Depending on your liver function you may have to delay or stop Aptivus treatment - if you are currently taking products containing: - rifampicin (used to treat tuberculosis) - cisapride (used to treat stomach problems) - pimozide or sertindole (used to treat schizophrenia) - quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder) - lurasidone (used to treat schizophrenia) - triazolam or oral midazolam (taken by mouth).
Vaše jetre, možda ćete morati odgoditi ili prekinuti liječenje Aptivusom - ako trenutno uzimate lijekove koji sadrže: - rifampicin (primjenjuje se u liječenju tuberkuloze) - cisaprid (primjenjuje se u liječenju želučanih problema) - pimozid ili sertindol (primjenjuju se u liječenju shizofrenije) - kvetiapin (primjenjuje se u liječenju shizofrenije, bipolarnog poremećaja i velikog depresivnog poremećaja) - lurasidon (primjenjuje se u liječenju shizofrenije) - triazolam ili oralni midazolam (uzimaju se oralno).
Narcotic analgesics Methadone 5 mg QD Methadone Cmax ↓ 55% Methadone AUC ↓ 53% Methadone Cmin ↓ 50%
Metadon Cmax ↓ 55% Metadon AUC ↓ 53% Metadon Cmin ↓ 50%
All patients * Includes patients who did not receive ENF and those who were previously treated with and continued ENF ** Mutations in HIV protease at positions L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, 58E, H69K, T74P, V82L/T, N83D or I84V ENF Enfuvirtide; TPV/r Tipranavir with ritonavir
* Uključuje bolesnike koji nisu primali ENF i one koji su prethodno primali ENF i to su liječenje nastavili i u pokusu ** Mutacije HIV proteaze na pozicijama L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, 58E, H69K, T74P, V82L/T, N83D, ili I84V ENF enfuvirtid; TPV/r tipranavir s ritonavirom
If you miss a dose of Aptivus or ritonavir by more than 5 hours, wait and then take the next dose of Aptivus and ritonavir at the regularly scheduled time.
Ako propustite dozu Aptivusa ili ritonavira za više od 5 sati, pričekajte i zatim uzmite sljedeću dozu Aptivusa i ritonavira u redovno vrijeme, prema režimu doziranja.
Stavudine
Stavudin
In such cases no dosage adjustment of zidovudine can be recommended (see section
U takvom slučaju nije potrebno podešavati dozu zidovudina (vidjeti dio 4.4).
Propyl gallate
Lanzoprazol Pantoprazol
If your child misses a dose of Aptivus or ritonavir by more than 5 hours, wait and then give the next dose of Aptivus and ritonavir at the regularly scheduled time.
Ako Vaše dijete propusti dozu Aptivusa ili ritonavira za više od 5 sati, neka pričeka i zatim uzme sljedeću dozu Aptivusa i ritonavira u redovno vrijeme, prema režimu doziranja.
No data are currently available on interactions of tipranavir, coadministered with low dose ritonavir, with protease inhibitors other than those listed above.
Trenutno nisu dostupni podaci o interakcijama tipranavira s niskom dozom ritonavira, s drugim inhibitorima proteaze osim gore navedenih.
STATEMENT OF ACTIVE SUBSTANCE(S) Each soft capsule contains 250 mg tipranavir
NAVOĐENJE DJELATNE(IH) TVARI Jedna meka kapsula sadrži 250 mg tipranavira
The concomitant use of Aptivus, co-administered with low dose ritonavir, with dihydroergotamine, ergonovine, ergotamine or methylergonovine is contraindicated due to potential serious and/or life threatening events (see section 4.3)
Istodobna primjena Aptivusa s niskom dozom ritonavira i dihidroergotamina, ergonovina, ergotamina, ili metilergonovina je kontraindicirana zbog potencijalnih teških i/ili fatalnih događaja (vidjeti dio 4.3)
Absorption of tipranavir, co-administered with low dose ritonavir, is reduced in the presence of antacids (see section 4.5).
Apsorpcija tipranavira s niskom dozom ritonavira je smanjena u prisustvu antacida (vidjeti dio 4.5).
It has not been shown that tipranavir is superior to these boosted comparator protease inhibitors in patients harbouring strains susceptible to these protease inhibitors.
Nije pokazana superiornost tipranavira spram kontrolnog tretmana u bolesnika koji su imali virusne sojeve osjetljive na kontrolne inhibitore proteaze.
Therefore Aptivus, co-administered with low dose ritonavir, should be given with food.
Stoga se Aptivus s niskom dozom ritonavira uzima zajedno s hranom.
Steady-state tipranavir/r Midazolam Cmax ↑ 3.7 fold Midazolam AUC ↑ 9.8 fold
Tipranavir/r u stanju ravnoteže Midazolam Cmax ↑ 3,7 puta Midazolam AUC ↑ 9,8 puta
TPV/r 500/100 mg, TPV/r 750/200 mg) represented extremes of hepatic enzyme induction and inhibition and bracketed the recommended dosage of Aptivus/r.
Ipak, rezultati mnogih od ovih ispitivanja o interakcijama mogu se ekstrapolirati u preporučeno doziranje, s obzirom da su primijenjene doze (npr. TPV/r 500/100 mg, TPV/r 750/200 mg) predstavljale ekstreme indukcije i inhibicije jetrenih enzima, te su obuhvatile preporučene doze Aptivusa/r.
Aptivus must be administered with low dose ritonavir to ensure its therapeutic effect (see section 4.2).
Aptivus se, u svrhu osiguranja terapijskog učinka, mora primjenjivati s niskom dozom ritonavira (vidjeti dio 4.2).
Co-administration of Aptivus, coadministered with low dose ritonavir, and rosuvastatin should be initiated with the lowest dose (5 mg/day) of rosuvastatin, titrated to treatment response, and accompanied with careful clinical monitoring for rosuvastatin associated symptoms as described in the label of rosuvastatin.
Istodobna primjena Aptivusa s niskom dozom ritonavira i rosuvastatina započinje najnižom dozom (5 mg/dan) rosuvastatina, titriranom do terapijskog odgovora, uz pažljivo kliničko praćenje radi nuspojava rosuvastatina.
Abacavir and zidovudine
Abakavir i zidovudin
P-gp activity is significantly inhibited after the first dose,
Aktivnost P-gp-a je značajno inhibirana nakon prve doze, ali je u stanju dinamičke ravnoteže uočena blaga indukcija.
Aptivus oral solution contains vitamin E. Your child should not take any additional vitamin E supplements.
Vaše dijete ne smije dodatno uzimati dodatke koji sadrže vitamin E.
Do not refrigerate or freeze After first opening of the bottle, the product can be used for 60 days.
Nakon prvog otvaranja boce, lijek se može koristiti 60 dana.
Mean decrease in viral load from baseline to week 48, according to tipranavir baseline mutation score and enfuvirtide use in RESIST patients
Prosječno smanjenje virusnog opterećenja od početka do 48. tjedna, u odnosu na „mutacijski skor“ i primjenu enfuvirtida u bolesnika u RESIST
Posology The recommended dose for children (age 2 to 12 years) is 375 mg/m2 Aptivus co-administered with
Preporučena doza za djecu (u dobi 2 do 12 godina) je 375 mg/m2 Aptivusa sa 150 mg/m2 ritonavira,
Induction of CYP 2C19 by tipranavir/r
Indukcija CYP 2C19 putem tipranavira/r
Rash consists of one or more of the preferred terms of rash, drug eruption, rash macular, rash papular, erythema, rash maculo-papular, rash pruritic, and urticaria
Jedan ili više preferiranih termina: osip, medikamentozna erupcija, makularni osip, papularni osip, eritem, makulopapularni osip, pruritički osip ili urtikarija
In the tipranavir and comparator arms median baseline CD4 cell counts were 158 and 166 cells/mm
Medijan početnog broja CD4 stanica u ispitivanoj skupini iznosio je 158 stanica/mm
Amber glass bottle, with two-piece plastic child-resistant closure (outer shell high density polyethylene (HDPE), inner shell polypropylene resin with a foamed laminated polyethylene liner.. Each pack contains 1 bottle of 95 ml oral solution and is supplied with a clear polypropylene 5 ml oral syringe, HDPE syringe tip cap and clear LDPE bottle-syringe adapter.
Svako pakiranje sadrži 1 bocu sa 95 ml oralne otopine, s priloženom prozirnom polipropilenskom oralnom štrcaljkom od 5 ml, HDPE zatvaračem za štrcaljku i prozirnim nastavkom za bocu i štrcaljku od polietilena niske gustoće (LDPE).
Each Aptivus capsule contains 250 mg of the active substance tipranavir.
Jedna Aptivus kapsula sadrži 250 mg djelatne tvari, tipranavira.
Recommendations concerning co-administration
Preporuke o istodobnoj primjeni
The concomitant use of Aptivus, co-administered with low dose ritonavir, with flecainide, propafenone or metoprolol is contraindicated (see section 4.3)
Istodobna primjena Aptivusa s niskom dozom ritonavira i flekainida, propafenona, ili metoprolola je kontraindicirana (vidjeti dio 4.3)
Antimalarial Halofantrine Lumefantrine No interaction study performed
Lumefantrin Nije provedeno ispitivanje interakcija
In pre- and post-natal development studies with tipranavir in rats, growth inhibition of pups was observed at maternally toxic doses approximating 0.8-fold human exposure.
U ispitivanjima pre- i postnatalnog razvoja u štakora, sistemska izloženost toksična za majku bila je oko 20% niža od sistemske izloženosti u ljudi pri preporučenim kliničkim dozama i rezultirala je inhibicijom rasta mladunaca.
The concomitant use of Aptivus, coadministered with low dose ritonavir, with abacavir is not recommended unless there are no other available NRTIs suitable for patient management.
Istodobna primjena Aptivusa, s niskom dozom ritonavira, i abakavira se ne preporučuje, osim ako on nije jedini NRTI prikladan za zbrinjavanje bolesnika.
The combined use of Aptivus, coadministered with low dose ritonavir, with either omeprazole or esomeprazole is not recommended (see section 4.4).
Kombinirana primjena Aptivusa s niskom dozom ritonavira i omeprazola ili esomeprazola se ne preporučuje (vidjeti dio 4.4).
Compared to the capsules, tipranavir exposure is higher when administering the same dose as oral solution.
U usporedbi s kapsulama, ista doza u obliku oralne otopine rezultira većom izloženošću tipranaviru.
If the co-administration with bupropion is judged unavoidable, this should be done under close clinical monitoring for bupropion efficacy, without exceeding the recommended dosage, despite the observed induction.
Sniženje vrijednosti bupropiona u plazmi javlja se vjerojatno zbog indukcije aktivnosti CYP2B6 i UGT ritonavirom praćenje radi učinkovitosti bupropiona, bez prekoračivanja preporučenog doziranja, usprkos primijećenoj indukciji.
Inhibition of CYP 3A4 and CYP 2D6 by tipranavir/r
Inhibicija CYP 3A4 i CYP 2D6 putem tipranavira/r
Digoxin 0.25 mg QD po
Digoksin 0,25 mg QD p.o.
Based on theoretical considerations, The concomitant use of Aptivus,
Temeljem teoretskih razmatranja, istodobna primjena tipranavira s
Examples include: - rifabutin and clarithromycin (antibiotics) - theophylline (used to treat asthma) - desipramine, trazodone and bupropion (used to treat depression; bupropion is also used for smoking cessation) - midazolam (when given by injection); midazolam is a sedative used to treat anxiety and to help you sleep - rosuvastatin or pravastatin (used to lower blood cholesterol) - colchicine (used to treat gout flares with normal kidney and liver function).
Primjeri uključuju: - rifabutin i klaritromicin (antibiotici) - teofilin (primjenjuje se u liječenju astme) - desipramin, trazodon i bupropion (primjenjuju se u liječenju depresije: bupropion se također primjenjuje u prekidu pušenja) - midazolam (kada se daje injekcijskim putem); midazolam je sedativ koji se primjenjuje u liječenju anksioznosti i kao pomoć u uspavljivanju - rosuvastatin ili pravastatin (primjenjuju se u snižavanju kolesterola u krvi) - kolhicin (koji se primjenjuje u liječenju naglih pogoršanja gihta uz urednu funkciju bubrega i jetre).
Among all randomised and treated patients, the median change from baseline in HIV-1 RNA at the last measurement up to Week 48 was -0.64 log10 copies/ml in patients receiving tipranavir with ritonavir versus -0.22 log10 copies/ml in the comparator PI/ritonavir arm.
Uzimajući u obzir sve randomizirane i liječene bolesnike medijan razlike HIV-1 RNA između zadnjeg mjerenja (najdulje nakon 48 tjedana) i vrijednosti prije početka liječenja, iznosio je -0,64 log10 kopija/ml za ispitivanu i0,22 log10 kopija/ml za kontrolnu skupinu.
The combined use of Aptivus, coadministered with low dose ritonavir, with proton pump inhibitors is not recommended (see section 4.4).
Kombinirana primjena Aptivusa s niskom dozom ritonavira i inhibitora protonske pumpe se ne preporučuje (vidjeti dio 4.4).
Aptivus oral solution co-administered with low dose oral solution ritonavir should be taken with food (see section 5.2).
Aptivus oralna otopina, primijenjena istodobno s niskom dozom oralne otopine ritonavira, uzima se s hranom (vidjeti dio 5.2).
With respect to mutations on codons 33, 82, 84 and 90 approximately 4% had no mutations, 24% had mutations at codons 82 (less than 1% of patients had the mutation V82L) and 90, 18% had mutations at codons 84 and 90 and 53% had at least one key mutation at codon 90.
Na početku studija, medijan broja mutacija u genu za proteazu iznosio je 16, a medijan broja primarnih mutacija gena za proteazu - D30N, L33F/I, V46I/L, G48V, I50V, V82A/F/T/L, I84V, i L90M - iznosio je 3. S obzirom na mutacije na kodonima 33, 82, 84 i 90, oko 4% bolesnika imalo je viruse bez mutacija, 24% je imalo mutacije na kodonima 82 (manje od 1% bolesnika je imalo mutaciju V82L) i 90, 18% je imalo mutacije na kodonima 84 i 90, a 53% imalo je najmanje jednu ključnu mutaciju na kodonu 90.
If a dose is missed by less than 5 hours, the patient should be instructed to take the missed dose immediately, and then to take the next dose of Aptivus and ritonavir at the regularly scheduled time.
U slučaju propuštanja doze za manje od 5 sati, bolesnika je potrebno uputiti da odmah uzme propuštenu dozu, te da zatim uzme sljedeću dozu Aptivusa i ritonavira u redovno vrijeme prema režimu doziranja.
The clinical relevance of this reduction in amprenavir concentrations has not been established.
Klinički značaj ovog smanjenja koncentracija amprenavira nije utvrđen.
administered with low dose ritonavir, should be separated by at least 2 hours to avoid formulation incompatibility.
Primjena želučanootporne formulacije didanozina i Aptivus mekih kapsula s niskom dozom ritonavira mora biti odvojena najmanje 2 sata radi izbjegavanja inkompatibilnosti formulacija.
Based on theoretical considerations tipranavir, co-administered with low dose ritonavir, is expected to increase itraconazole or ketoconazole concentrations.
Temeljem teoretskih razmatranja, očekuje se da tipranavir s niskom dozom ritonavira povećava koncentracije itrakonazola ili ketokonazola.
Aptivus with ritonavir should not be used in treatment-naïve patients.
Aptivus s ritonavirom se ne smije primjenjivati u bolesnika koji prethodno nisu liječeni antiretrovirusnim lijekovima.
CYP 3A4 inhibition by tipranavir/r co-administered with low dose ritonavir, with alfuzosin is contraindicated.
CYP 3A4 inhibicija putem tipranavira/r alfuzosina je kontraindicirana.
The concomitant use of Aptivus, coadministered with low dose ritonavir with zidovudine is not recommended unless there are no other available NRTIs suitable for patient management.
Istodobna primjena Aptivusa s niskom dozom ritonavira i zidovudina se ne preporučuje, osim ako on nije jedini NRTI prikladan za zbrinjavanje bolesnika.
No interaction study performed
Nije provedeno ispitivanje interakcija
Tipranavir phenotypic resistance
Fenotipska otpornost na tipranavir
Switching from Aptivus capsules to the oral solution Aptivus capsules are not interchangeable with the oral solution.
Aptivus kapsule nisu zamjenjive s oralnom otopinom.
Lamivudine 150 mg BID (TPV/r 750/100 mg BID)
Lamivudin 150 mg BID (TPV/r 750/100 mg BID)
Coadministration of Aptivus with ritonavir, with St. John's wort is expected to substantially decrease tipranavir and ritonavir concentrations and may result in sub-optimal levels of tipranavir and lead to loss of virologic response and possible resistance to tipranavir.
Očekuje se da istodobna primjena gospine trave znatno smanjuje koncentracije tipranavira i ritonavira te može rezultirati nedostatnim koncentracijama tipranavira i dovesti do gubitka virusnog odgovora i moguće otpornosti na tipranavir.
Steady-state tipranavir/r Digoxin Cmax ↓ 38% Digoxin AUC ↔
Tipranavir/r u stanju ravnoteže Digoksin Cmax ↓ 38% Digoksin AUC ↔